Thibaut  Mongon net worth and biography

Thibaut Mongon Biography and Net Worth

Thibaut Mongon is Executive Vice President, Worldwide Chairman, Consumer Health at Johnson & Johnson. He serves on the corporation’s Executive Committee and chairs the Consumer Health Leadership Team. In his role, Thibaut leads the global development of J&J’s personal health portfolio that spans OTC/self care, skin health/beauty, oral care, baby care, women’s health and wound care, generating approximately $14 Billion in revenue. Leading operations in more than 140 countries with 19,000 associates, Thibaut is steward of a differentiated portfolio of iconic brands, including Tylenol®, Nicorette®, Zyrtec®, Neutrogena®, Aveeno®, Listerine®, OGX®, BAND-AID® and Johnson’s®.

Under his leadership, the Consumer Health team accelerated growth through portfolio optimization with a singular focus on personal health and a concentration on markets where Consumer Health could make the biggest impact. To help people live healthier lives every day, Thibaut mobilized an end-to-end approach to life-enhancing innovation that delivers solutions rooted in science and endorsed by professionals. Adept at navigating consumer and market shifts, Thibaut has advanced a digital-first ambition to grow ecommerce and digital capabilities to create frictionless interactions with consumers and health care professionals, drive innovation and improve supply chain’s agility. He is also invested in delivering on an ambitious sustainability agenda.

Thibaut is a seasoned global leader with more than 20 years at Johnson & Johnson. He inspires a one team mindset, leading with purpose and always staying grounded in Our Credo. He draws on his knowledge working across five continents and all three sectors of Johnson & Johnson to empower an agile, end-to-end organization to develop solutions that improve health outcomes for 1.2 billion consumers globally.

Before being elevated to his current role, Thibaut served as Company Group Chairman, Johnson & Johnson Consumer Health Asia-Pacific. From 2014 until early 2019, Thibaut led the transformation of this region into an engine of accelerated revenue growth by creating a vibrant pipeline of consumer-centric innovation. He also drove significant value through both external partnerships and strategic acquisitions, helping to future-proof the portfolio.

Thibaut joined Johnson & Johnson in 2000 as Director of Marketing for the Vision Care group (Medical Devices) in France and subsequently held general management positions as Country Manager France, Belgium and North Africa, Managing Director Latin America, and President Asia-Pacific. Thibaut transitioned to the Pharmaceutical Group of Johnson & Johnson in 2012 as the Global Commercial Strategy Leader for the Neuroscience therapeutic area, based in the U.S.

Prior to joining Johnson & Johnson, Thibaut worked for Bormioli in Italy and Danone in France.

Thibaut serves on the board of the Consumer Goods Forum.

Thibaut holds degrees in Business Administration from the KEDGE Bordeaux Business School and a Master of Business Administration from INSEAD.

What is Thibaut Mongon's net worth?

The estimated net worth of Thibaut Mongon is at least $5.98 million as of November 4th, 2022. Mr. Mongon owns 40,133 shares of Johnson & Johnson stock worth more than $5,984,633 as of April 23rd. This net worth estimate does not reflect any other assets that Mr. Mongon may own. Learn More about Thibaut Mongon's net worth.

How do I contact Thibaut Mongon?

The corporate mailing address for Mr. Mongon and other Johnson & Johnson executives is ONE JOHNSON & JOHNSON PLZ, NEW BRUNSWICK NJ, 08933. Johnson & Johnson can also be reached via phone at (732) 524-0400 and via email at [email protected]. Learn More on Thibaut Mongon's contact information.

Has Thibaut Mongon been buying or selling shares of Johnson & Johnson?

Thibaut Mongon has not been actively trading shares of Johnson & Johnson within the last three months. Most recently, Thibaut Mongon sold 35,246 shares of the business's stock in a transaction on Friday, November 4th. The shares were sold at an average price of $171.18, for a transaction totalling $6,033,410.28. Following the completion of the sale, the vice president now directly owns 40,133 shares of the company's stock, valued at $6,869,966.94. Learn More on Thibaut Mongon's trading history.

Who are Johnson & Johnson's active insiders?

Johnson & Johnson's insider roster includes Dominic Caruso (VP), Robert Decker (CAO), Joaquin Duato (CEO & Director ), Peter Fasolo (VP), Alex Gorsky (CEO), William Hait (Insider), Ronald Kapusta (CAO), Ashley McEvoy (EVP), Thibaut Mongon (VP), William Perez (Director), Michael Sneed (COO), Paulus Stoffels (VP), James Swanson (Insider), Jennifer Taubert (EVP), Kathryn Wengel (EVP), Joseph Wolk (CFO), and Joseph Wolk (Exec. VP & CFO ). Learn More on Johnson & Johnson's active insiders.

Are insiders buying or selling shares of Johnson & Johnson?

During the last year, insiders at the sold shares 5 times. They sold a total of 110,285 shares worth more than $17,306,967.44. The most recent insider tranaction occured on February, 16th when Major Shareholder & Johnson Johnson sold 3,725 shares worth more than $96,142.25. Insiders at Johnson & Johnson own 0.2% of the company. Learn More about insider trades at Johnson & Johnson.

Information on this page was last updated on 2/16/2024.

Thibaut Mongon Insider Trading History at Johnson & Johnson

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/4/2022Sell35,246$171.18$6,033,410.2840,133View SEC Filing Icon  
3/17/2022Sell23,681$176.25$4,173,776.25View SEC Filing Icon  
See Full Table

Thibaut Mongon Buying and Selling Activity at Johnson & Johnson

This chart shows Thibaut Mongon's buying and selling at Johnson & Johnson by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Johnson & Johnson Company Overview

Johnson & Johnson logo
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. Its MedTech segment provides Interventional Solutions, including electrophysiology products to treat heart rhythm disorders; the heart recovery portfolio, which includes technologies to treat severe coronary artery disease requiring high-risk PCI or AMI cardiogenic shock; and neurovascular care that treats hemorrhagic and ischemic stroke. this segment also offers an orthopaedics portfolio that includes products and enabling technologies that support hips, knees, trauma, spine, sports, and other; surgery portfolios comprising advanced and general surgery technologies, as well as solutions for breast aesthetics, ear, nose, and throat procedures; contact lenses under the ACUVUE Brand; and TECNIS intraocular lenses for cataract surgery. It distributes its products to wholesalers, hospitals, and retailers, as well as physicians, nurses, hospitals, eye care professionals, and clinics. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.
Read More

Today's Range

Now: $149.12
Low: $147.31
High: $150.27

50 Day Range

MA: $155.97
Low: $144.45
High: $162.73

2 Week Range

Now: $149.12
Low: $143.13
High: $175.97

Volume

10,114,691 shs

Average Volume

7,317,319 shs

Market Capitalization

$359.35 billion

P/E Ratio

9.30

Dividend Yield

3.22%

Beta

0.53